CD38 displays lateral association with the HIV-1 receptor CD4. This association is potentiated by the HIV-1 envelope glycoprotein gp120. The aim of this work was to evaluate the CD38 role in T cell susceptibility to HIV-1 infection. Using laboratory X4 HIV-1 strains and X4 and X4/R5 primary isolates, we found that CD38 expression was negatively correlated to cell susceptibility to infection, 
attachment involves interaction of the HIV-1 envelope glycoprotein gp120 with CD4 acting as the main viral receptor, and several members of the chemokine receptor family acting as co-receptors (1) . Three co-receptors play a crucial role in infection of different types of human cells. CXCR4 (also known as fusin or LESTR) is the receptor for the stromalderived factor (SDF-1) and is mainly used by the 'lymphocyte-tropic' X4 HIV-1 strains, which generally develop in the advanced stages of infection (3, 4) . CCR5 is a receptor for the ␤-chemokines macrophage inflammatory protein-1␣ (MIP-1␣), MIP-1␤, and RANTES, and is mainly used by the 'macrophage-tropic' R5 HIV strains, which predominate in the early stages and can infect many cell types (3, 4) . CCR3 is the receptor for eotaxin and is considered to be an important HIV-1 co-receptor on microglia (5) .
Other cell-surface proteins modulate susceptibility either by direct interference with virus attachment or through their signaling pathways. For instance, expression of CD26 or CD44 promotes and triggering of CD28 either increases or decreases susceptibility to several viral strains (6 -10) . Moreover, during viral budding from infected cells, several cell-surface molecules are incorporated into viral envelopes. Some are adhesion molecules and contribute to viral attachment by interacting with their physiological ligands of the target cells (1, 11) .
We have previously shown that CD4 binding by gp120 induces lateral associations with several leukocyte surface molecules (12, 13) . Because HIV-1 infection depends on multiple intermolecular interactions on the cell surface and precise steric interactions, we suggested that some of these associations positively or negatively influence cellular infection (12) : CD38 was an attractive candidate, its expression being negatively correlated with HIV-1 infection in a panel of CD4 ϩ T cell lines (12) (13) (14) .
Human CD38, a single-chain transmembrane type II glycoprotein, is surface-expressed by early hematopoietic cells, lost by mature cells, and re-expressed on cell activation (15) . It is detectable at high levels on mature thymocytes and activated T cells and at low levels on resting naive cells (CD45RA ϩ R0 Ϫ cells), whereas resting memory cells (CD45RA Ϫ R0 ϩ cells) are CD38 Ϫ (15, 16) . CD38 is thought to exercise the following three functions on T cells: 1) as an ectoenzyme, it leads to the formation of cyclic ADP-ribose, a crucial compound in regulation of intracellular Ca 2ϩ (15, 17) ; 2) as an adhesion molecule, it mediates the interactions between leukocytes and vascular endothelial cells through CD31 (15, 16, 18) ; 3) as a molecule involved in transmembrane signaling, its engagement results in Ca 2ϩ mobilization, costimulates cell activation, and modulates cytokine production (15) . CD38 signaling exploits other molecules specialized in signaling, such as CD3 in T cells (19) , BCR in B lymphocytes, (20) , and CD16 in natural killer (NK) cells (R. Mallone, A. Funaro, and F. Malavasi, unpublished) . By contrast, the relationship between its signaling and ectoenzyme functions is not known, and CD38-induced Ca 2ϩ mobilization seems to be independent from its enzyme activity (21) .
In HIV-1 infection, CD38 has so far been studied mainly from a prognostic perspective. Its expression is high on peripheral blood lymphocytes in primary infection, decreases during transition to the asymptomatic phase, and then increases during progression to AIDS (22) . High expression on peripheral blood CD8 ϩ T cells is a negative prognostic factor and is decreased by successful HAART (highly active antiretroviral therapy) in both adults and children (22) (23) (24) (25) . By contrast, high expression on CD4 ϩ T cells is positively correlated with survival in children (26, 27) . These findings have been attributed to the ability of CD38 to mark activation of the immune response (23) . However, the fact that CD38 association with CD4 is increased by gp120 (12, 13) and its expression is correlated with HIV-1 infection, suggests that its role is direct (14, 28) . The aim of the present work was to investigate this possibility by using human and mouse cell lines transfected with the human CD38 cDNA and assessing the effects of CD38 expression on various steps of HIV-1 replication.
MATERIALS AND METHODS

Monoclonal antibodies
Fluorescein isothiocyanate (FITC)-labeled mouse monoclonal antibodies (mAbs) to human CD4 were purchased from Coulter, Hialeah, FL; R-phycoerythrin (R-PE)-conjugated mAbs to human CXCR-4 (12G5) were from PharMingen, San Diego, CA; FITC-conjugated mouse anti-HIV-1 p24 mAbs were from Virostat, Portland, ME; unconjugated anti-CD26 mAbs were a generous gift of Dr. E. C. Bosmans, Eurogenetics, Belgium; FITC-conjugated anti-CD38 mAbs (IB4) were obtained as described previously (29) ; FITC-conjugated rabbit anti-murine immunoglobulins were from Pierce, Rockford, IL. Appropriate isotype-matched mAbs were used as negative controls.
Cells
The following human T cell lines were used: H9, Supt-1, C 8166, MT-2, MT-4, and CEMx174 (14, 30 -33) . They were grown in RPMI-1640 medium (Life Technologies, Inc., Gaithersburg, MD), supplemented with 10% (v/v) fetal calf serum (FCS; Techno-Genetics, Milan, Italy), 200 g/ml glutamine (Merck, Darmstadt, Germany), and 40 g/ml gentamicin (Schering-Plow, Milan, Italy).
SR.D10-CD4 Ϫ. F1 was a CD4 Ϫ mutant cell line cloned from the mouse CD4 ϩ TH2 cell line D10.G4.1 (34) . It was grown in Click medium with 10% FCS, 9% (v/v) ␤-mercaptoethanol, 5 U/ml interleukin-2 (IL-2); 10 U/ml IL-4, and 25 pg/ml IL-1␣.
Expression vectors
The SR.hCD4 line expressing human CD4 was produced by transfecting the human CD4 cDNA inserted in the pNeoSR␣ plasmid in SR.D10.CD4
Ϫ .F1 cells as previously reported (35) . CD38 transfectants were produced by transfecting the human CD38 cDNA in SR.D10.CD4
Ϫ F1, SR.hCD4, and MT4 cells. Full-length human CD38 cDNA (generous gift of Dr. D. Jackson, Oxford, UK) was excised from the pCDM8 plasmid with XbaI and cloned into the corresponding site of a pcDNA3.1/zeo expression vector carrying ampicillin/zeocin resistance, or pcDNA3/neo carrying ampicillin/neomycin resistance. Sequencing of the CD38 cDNA after cloning ruled out the presence of mutations in the sequence and confirmed the correct position of the cDNA insertion in the plasmid. Plasmids were linearized with PvuI and transfected at 10 g/ml in the appropriate cell line [5ϫ10 6 cells in 0.8 ml of phosphate-buffered saline (PBS)] by electroporation at 960 F and 260 V using a Gene Pulser (Bio-Rad, Hercules, CA). Transfectants carrying pcDNA3/neo were grown in culture medium containing 0.8 mg/ml G-418 (selection medium), whereas transfectants carrying pcDNA3.1/zeo were grown in medium containing 0.8 mg/ml zeocin.
Flow cytometry
To determine the expression of cellular and viral antigens, cells were pooled and washed in PBS with NaN 3 (0.02%) and bovine serum albumin (2%; PBS A/A), and subsequently treated as follows.
To detect surface antigen expression, cells were suspended in PBS A/A (2.5ϫ10 6 cells/ml) and incubated with saturating concentrations of the appropriate mAb. The negative control samples were incubated with isotype-matched mAbs. When unconjugated mAbs were used, cells were washed in PBS A/A and subsequently incubated with FITC-labeled goat antimouse Ig antibodies under the same conditions. Finally, the cells were washed three times and immediately analyzed by flow cytometry (FACScan, Becton-Dickinson, Mountain View, CA).
To determine the percentage of infected cells, pellets were fixed, permeabilized, and stained with mAbs to HIV-1 p24 using a commercially available kit (Caltag, Burlingame, CA), as described previously (32, 36) . The fixed samples were analyzed by flow cytometry.
Fluorescence data were collected on a 4-decade log scale and the relative fluorescence intensity was stated as the median channel number (MeFI). Log values were mathematically converted to linear fluorescence intensity and the control antibody values for each experiment were subtracted. Fluorescence was also evaluated in terms of percentage of fluorescent cells beyond the threshold value established using cells stained with the isotype control reagents.
Infection with HIV-1
Stocks of HIV-1 IIIB (a laboratory X4 strain) were obtained from the supernatant of H9 III B cells, a persistently HIV-1-infected H9 cell line, as described elsewhere (30) . Stocks of HIV-1 P1 (a laboratory-adapted X4 strain) were obtained from acutely-infected C 8166 cells, as described previously (33) . Stocks of HIV-1 BAL (a laboratory-adapted R5 strain) (37) were obtained from Dr. C. Balotta, 'Sacco' Hospital, Milan, Italy. Stocks of the X4 and R5/X4 primary isolates were obtained from Dr. F. Piro ('Amedeo di Savoia' Hospital, Turin, Italy) and Dr. G. Poli (DIBIT, Milan, Italy), respectively. Both primary isolates were grown in phytohemagglutinin (PHA)-activated peripheral blood mononuclear cells (PBMC). Stocks of pRRL.sin.hPGK.GFP, a lentiviral vector pseudotyped with the vesicular stomatitis virus (VSV)-G envelope glycoprotein (38) , were a generous gift of Dr. L. Naldini (IRCC Candiolo, Italy).
Viral stocks were titrated immunoenzymatically using p24 antigen enzyme-linked immunosorbent assay (ELISA) kits and biologically by the 50% end point dilution method, using MT-2 cells (laboratory strains) or PHA-activated PBMC (primary isolates). The infectious titer was expressed as cell culture infecting doses (CCID 50 )/ml (39) .
Cells to be infected were suspended at 5 ϫ 10 5 cells/ml in fresh culture medium 24 h before the infection. Cell pellets were infected with the HIV-1 stock suspensions at a titer of 5-10 ϫ 10 5 CCID 50 /ml; the number of cells was adjusted so as to have a multiplicity of infection (MOI) of ϳ1. The cells were then incubated at 37°C for 2 h, washed three times with PBS, resuspended at 2.5 ϫ 10 5 cells/ml in fresh culture medium, transferred to 24-well plastic microtiter trays (Nunc, Kamstrup, Denmark), and incubated at 37°C in a 5% CO 2 humidified atmosphere. At different times after infection, cell viability was assessed microscopically by the trypan blue-dye exclusion method. In the case of MT-4 cells, which display a typical clustered pattern, clusters were dissociated by pipetting, and reclustering was examined microscopically after a 3-h incubation at 37°C (14, 30) . Proviral DNA was detected by PCR 2 days after infection. Cells were lysed in 500 l of 500 mM Tris-HCl pH 9, 2 mM EDTA, 10 mM NaCl, 1% SDS plus 80 ng of proteinase K/ml at 55°C for 24 h. Cellular DNA was prepared by phenol extraction, followed by ethanol precipitation. DNA content was determined spectrophotometrically at 260 nm and equal amounts of DNA for each experimental condition underwent serial dilutions that were amplified by PCR using primers for a conserved gag region sequence (sense: 5Ј-ATAATCCAC-CTATCCCAGTAGGAGAAAT-3Ј; anti-sense: 5Ј-TTTGGTC-CTTGTCTTATGTCC-AGAATGC-3Ј), detecting full-length, double-stranded viral DNA in both the integrated and unintegrated form. The following amplification conditions were employed: denaturation (5 min at 94°C) was followed by 35 cycles of denaturation (1 min at 94°C), annealing (1 min at 55°C), extension (1 min at 72°C), and final incubation (10 min at 72°C). The amplification products of 114 bp obtained were electrophoresed on 3% agarose gels and visualized by ethidium bromide staining (37) . As a control, the human gene bax was amplified by PCR in the same DNA preparations (sense: 5Ј-TCTCCTGCAGGATGATTGC-3Ј; anti-sense: 5Ј-TC-CCCAGGTCCTCACAGAT-3Ј). A standard curve for the quantification of proviral DNA copies was prepared using serial 10-fold dilutions of the DNA extracted from a suspension of 8E5 cells, containing one proviral copy per cell (40) , and amplified under the same conditions. Amplified products of the correct size were quantified using Gel Doc (Bio-Rad, Hercules, CA). The intensity units ϫ mm 2 (INTϫmm 2 ) of the serially diluted standard samples were used to construct the standard curve, using the least squares method. The proviral copy numbers of the experimental samples were calculated by reporting the values of the last positive sample dilution on the standard curve.
HIV-1 binding to cells
HIV-1 binding to cells was evaluated as previously reported (41) . Briefly, 10 6 cells were incubated with 1 ml of the viral suspensions (titer: 10 ng of p24/ml) for 2 h at 37 or 4°C. Cells were then washed twice in PBS, lysed in 500 l PBS with 0.5% Triton X-100 (v/v), and p24 was quantitated immunoenzymatically in cell lysates using an ELISA kit (NEN TM Life Science Product, Inc., Boston, MA).
Cell staining with purified HIV-1 gp120 was evaluated by incubating cells (2.5ϫ10 6 cells/ml) with saturating concentrations (10 g/ml) of FITC-conjugated gp120 (Intracell Corp, London, UK) in PBS A/A for 30 min at 4°C. Cells were then washed and analyzed by flow cytometry. The negative control samples were incubated with PBS A/A alone.
FRET assay
The OKT4 mAb (ATCC) was conjugated to Cy3 dye with the FluoroLink-Ab Cy3 Labeling Kit (Amersham, (42) . FITC was excited at 488 nm and Cy3 emissions were collected at Ͼ600 nm. Data from 10,000 cells/test were stored in 'list mode' and analyzed with LYSYS II software (Becton Dickinson). The median linear channel of fluorescence was calculated and used as the indicator for the presence (a positive shift over background) or absence (no shift or negative shift) of energy transfer.
RESULTS
Cell phenotype and susceptibility to HIV-1 infection
The first step was to compare expression of CD38 and infection by the X4 HIV IIIB 
infection by flow cytometry (IF%), negatively correlated to the CD38 expression level (Table 1) , evaluated both as MeFI and proportion of positive cells (r ϭ Ϫ0.92 and Ϫ0.87, respectively). A similar correlation was obtained between CD38 expression and the proportion of dead cells at 5 days after infection (rϭϪ0.95). These results were in line with our previous observations with different approaches (14) . By contrast, IF% and cytopathic effects did not correlate with the expression levels of CD4 and CXCR4, nor of activation markers other than CD38 (CD26, CD71, HLA Class II).
HIV-1 replication in human transfectants expressing CD38
These data suggested that CD38 is a negative regulator of HIV-1 infection, even though differences in susceptibility due to other unknown features of the cell lines, such as differences in growth kinetics or differential expression of molecules other than CD38, could not be ruled out. To address this issue, we transfected the human CD38 cDNA (inserted in the pcDNA3.1neo plasmid) into MT-4 cells and evaluated HIV-1 infection of transfected clones expressing different levels of CD38. MT-4 cells were chosen because they had the lowest CD38 expression and the highest susceptibility to infection. Three transfectants expressing low (MT-4.38L), intermediate (MT-4.38I), and high (MT-4.38H) levels of CD38, respectively, were selected. A control mock transfectant (MT-4.M) was produced by transfecting MT-4 cells with the empty pcDNA3.1neo plasmid (Fig. 1) . In all transfectants, expression of CD4 and CXCR-4, as assessed by immunofluorescence and flow cytometry, was similar to that displayed by parental MT-4 cells (data not shown). Transfectants and parental cells were incubated with HIV-1 IIIB , washed, and cultured at 37°C. Infection was evaluated in terms of p24 release in the supernatants. Results indicate that HIV-1 replication was negatively correlated to CD38 expression (Fig. 2) . At day 2 and day 5 after infection, parental MT-4 cells and mock MT-4-M cells displayed the highest levels of p24, followed in order by MT-4.38L, MT-4.38I, and MT-4.38H. In MT-4M cells, maximal levels of p24 were reached at day 5 after infection, and in MT-4.38 cells at day 7. At the latter time, differences were no longer significant, suggesting that CD38 affects early events of infection. In MT-4.38I and MT-4.38H, the low levels of virus replication were strictly paralleled by reduced cytopathic effects, as shown by the cell viability curves (Fig. 2) . Similar results were obtained when cytopathic effects were assessed as loss of ability to form cell clusters in infection driven by HIV-1 IIIB (data not shown). In MT-4 cells, in fact, HIV-1 IIIB acts as a slow/low syncytium-inducing strain whose cytopathic effect consists of loss of cell ability to cluster and is strictly correlated to the level of viral replication (14, 30) . When infected with HIV-1 IIIB , MT-4.38I and MT-4.38H cells maintained a partial ability to form clusters, whereas MT-4.38L, MT-4.M, and parental cells lost this ability. Similar impairment of HIV-1 replication in CD38-expressing cells was also observed by using another laboratory-adapted X4 strain (HIV-1 P1 ; data not shown).
To investigate whether the inhibitory effect of CD38 expression on HIV replication was restricted to laboratory-adapted HIV-1 strains, we used two primary isolates, an X4 rapid/high syncytium-inducing and an X4/R5 slow/low syncytium-inducing. The results showed that both primary isolates had lower replication levels in CD38-expressing cells than in parental CD38-negative MT4 cells (Fig. 3) .
To assess whether CD38 affected the proviral DNA formation, we evaluated HIV-1 proviral genome in cellular DNA extracted from HIV-1 IIIB -infected MT-4.38H and MT-4.M cells by semi-quantitative PCR on day 2. The amount of proviral DNA was lower in MT-4.38H cells than in MT-4.M cells (Fig. 4) .
HIV-1 binding to mouse T cell expressing the human CD4 and/or CD38
These data suggested that CD38 expression could affect some event(s) preceding proviral DNA com- pletion. One possibility was that the lateral association of CD38 with CD4 interferes with viral binding. To investigate this possibility, we used mouse T cells that can be rendered susceptible to HIV binding by transfection with human CD4, although they remain non-permissive for productive infection. Therefore, we transfected human CD4 (inserted in the pNeoSRa plasmid) and/or CD38 (inserted in the pcDNA3.1zeo plasmid) in different combinations into the mouse SR.D10.CD4
Ϫ .F1 T cell clone, a CD4
Ϫ variant of the D10 TH2 T cell clone. Three clones expressing human CD4 (SR.hCD4), human CD38 (SR.hCD38), or both molecules (SR.hCD4.38), respectively, were selected (Fig. 5) . Because CD4 and CD38 display a basal level of lateral association in human T cells (12), we used FRET to evaluate whether human CD4 and CD38 maintained lateral associations in the murine environment. These experiments showed that energy transfer was obtained when SR.hCD4.38 cells stained with the Cy3-conjugated mAb to CD4 were co-stained with the FITC-conju- gated mAb to CD38. In contrast, no transfer was detected when they were co-stained with FITCconjugated control mAbs to mouse CD2 or CD3 (Fig. 6) .
The murine clones were used to evaluate the effects of CD38 expression on CD4-dependent virus/cell binding in the absence of other human molecules. Moreover, they did not express endogenous murine CD38 and CD4 (35) , thus avoiding interference of the human molecules with their mouse homologs. Transfectants and parental cells were incubated with HIV-1 IIIB for 2 h at 37°C, washed, and lysed. Cell-associated p24 was evaluated by ELISA in cell lysates (Fig. 7A) . SR.hCD4 cells displayed higher levels of cell-associated p24 than parental and SR.hCD38 cells. The doubletransfectant SR.hCD4.38 displayed significantly lower levels than those displayed by SR.hCD4 cells and similar to those displayed by CD4 Ϫ clones. The difference cannot be attributed to discrepancies in expression levels of human CD4, which were similar in SR.hCD4 and SR.hCD4.38 cells. Similar results were obtained using HIV-1 P1 , and performing the experiments at 4°C (data not shown). Because at 4°C the entry process is significantly reduced, these results support the hypothesis that CD38 carries out its inhibitory effects at the step of HIV-1 binding to target cells. The generality and specificity of this effect was further investigated by incubating cells with the R5 HIV-1 BAL strain and using an HIV-1 vector pseudotyped with the VSV-G envelope glycoprotein as a positive control. Figure 7B shows that SR.hCD4.38 displayed higher levels of cell-associated p24 than those displayed by SR.hCD4 cells where HIV-1 BAL was used, whereas no differences were found where the pseudotyped vector was used.
To further confirm the possibility that CD38 inhibits HIV-1 binding to target cells, cells were incubated with FITC-labeled HIV-1 IIIB gp120 for 30 min at 4°C, washed, and analyzed by flow cytometry. We found that gp120 staining was significantly lower in CD4 ϩ
CD38
ϩ cells than in their CD38 Ϫ counterparts ( Table 2) .
DISCUSSION
This work shows that CD38 expression negatively modulates CD4
ϩ T cell susceptibility to infection by different HIV-1 strains. This effect was initially suggested by evaluating the correlation between CD38 expression levels and susceptibility to infection in several human CD4 ϩ T cell lines. The results were then confirmed by transfecting the CD38 gene in a human CD4
ϩ CD38 Ϫ T cell line and in a murine T cell clone expressing human CD4. The results showed that productive infection was significantly delayed in cells expressing high levels of CD38. This effect was not restricted to laboratory-adapted X4 virus strains, since it was observed also with X4 and X4/R5 primary isolates.
The effect seemed to be mediated by early events in the replication cycle of HIV because 1) reduction of virus yield was maximal at early times of infection and 2) at 48 h after infection, cells expressing high CD38 levels displayed lower levels of full-length proviral DNA than cells expressing low CD38 levels. It is likely that the effect is mainly exerted at pre-entry stages because it was detectable in binding experiments with whole virus or purified gp120 and was detectable in both human (data not shown) and murine cells.
Inhibition of HIV-1 infection by the lateral association between CD38 and CD4 potentiated by gp120 was postulated in earlier studies (12) (13) (14) . The ability of gp120 to recruit CD38 seems to be highly conserved, since it was detected with glycoproteins derived from HIV-1 IIIB , HIV-1 SF2 , HIV-1 MN , and HIV-1 451 (13). Moreover, it did not presumably involve chemokine receptors because no lateral association was detected between CD38 and CXCR4 or CCR5 in the presence or absence of gp120 (U. Dianzani, personal observation). It could be that CD38 docking to CD4 affects the gp120 interaction with CD4 and/or viral co-receptors by steric interference. However, we cannot rule out the possibility that steps following gp120/CD4 interaction may also be affected by CD38.
The results with CD38 ϩ transfectants minimize the possibility that the negative correlation between CD38 expression and HIV-1 infection is due to factors independently controlling both variables. This possibility was raised by the observation that retinoic acid-responsive elements (RARE) control the CD38 gene as well as the expression of HIV-1: endogenous RARE positively regulate the CD38 gene, whereas viral RARE in the long-terminal repeats (LTR) negatively regulate HIV-1 genes (28, 43). CD38 expression, however, was not under the control of RARE in transfectants.
Inhibition could also be linked to the enzymatic or co-stimulatory functions of CD38. CD38 produces nicotinamide (NAm), a compound reported to inhibit HIV-1 replication and cytopathogenicity (14, 44) probably through inhibition of poly(ADP-ribose) polymerase (45) . This possibility seems to be unlikely because the concentrations of NAm required to inhibit HIV-1 replication are much greater than those produced by CD38 in cell culture (P. Deterre, personal communication). Alternatively, co-stimulation might enable CD38 to inhibit in the same manner as CD28, whose triggering can decrease cell susceptibility to macrophage-tropic HIV-1 strains by inhibiting expression of CCR5 (46) . However, this possibility appears equally unlikely because CD38-mediated inhibition was detectable in the mouse model in the absence of viral co-receptors and productive infection. It was also detectable in shortterm binding experiments at 4°C, which minimized the effect of putative signals triggered by gp120 through CD38.
The inhibition of HIV-1 replication by CD38 expression may account for the lower susceptibility of resting/ naive (CD45RA ϩ ) than memory (CD45R0 ϩ ) CD4
ϩ T cells (47) (48) (49) , since resting naive cells constitutively express CD38, whereas resting memory cells are CD38 Ϫ (16) . Moreover, it may play a role in the favorable prognostic value of high levels of CD38 on CD4 ϩ cells in HIV ϩ children (26) and in the relative resistance to HIV-1 infection shown by children born to HIV ϩ mothers (50) . CD38 expression, in fact, is basically higher in children than in adults, whereas the highest levels are found in newborns, who have high counts of recent thymic emigrants and naive T cells (51) (52) (53) . By contrast, our observation is in apparent contrast with the notion that PHA-activated T cells, which express high levels of CD38 (CD38 bright ), are more susceptible to HIV infection than resting T cells. A reasonable speculation is that CD38-mediated protection may be highly effective in resting CD38 bright cells, such as recent thymic emigrants and naive cells, but not in activated CD38 bright cells, which express a different pattern of molecules involved in viral binding and entry (such as chemokine receptors, CD26, or CD44) and are much more efficient in supporting viral replication at post-entry levels, which may overwhelm inhibition by CD38 (41, 51, 54) . Therefore, CD38-mediated protection may be highly effective in children, whose CD38 bright cells are predominantly resting cells, but not in adults, where they are predominantly activated (53) .
In conclusion, our data suggest that CD38 expression negatively modulates lymphocyte susceptibility to CD4-dependent infection by HIV-1, probably by inhibiting the gp120/CD4-dependent virus/cell binding. It is noteworthy that CD38 may also be expressed by cells of the monocyte/macrophage lineage, another crucial HIV-1 target (28). In this regard, we are currently developing a model to test whether the CD38-related inhibitory effects found in this study may be extended to macrophage infection by R5 HIV-1 strains.
To our knowledge, this is the first report of a naturally occurring surface molecule capable of directly inhibiting susceptibility to HIV-1 infection. Elucidation of the inhibitory mechanism(s) of CD38 may help to clarify those of HIV-1 infection and provide ways of preventing it. Current antiretroviral drugs inhibit after HIV-1 attachment/entry. Strategies aimed at blocking such entry are being extensively sought in the effort to inhibit HIV-1 replication at several steps (55) .
